Syros Pharmaceuticals, INC 8-K filings

Syros Pharmaceuticals has fully repaid its debt to Oxford Finance LLC, settling its obligations under the loan and security agreement.

Syros Pharmaceuticals announces its decision to voluntarily delist from Nasdaq and deregister with the SEC due to financial constraints and the failure of a key clinical trial.

Syros Pharmaceuticals has received notices from Nasdaq for failing to meet minimum bid price and market capitalization requirements, placing its listing status at risk.

Syros Pharmaceuticals has entered into a fifth amendment to its loan agreement with Oxford Finance, securing a forbearance period while it pursues a sale of assets to repay its debt.

Syros Pharmaceuticals is undergoing a significant restructuring, including a 94% workforce reduction and leadership changes, after a Phase 3 trial failure.

Syros Pharmaceuticals' SELECT-MDS-1 Phase 3 trial for tamibarotene in higher-risk myelodysplastic syndrome did not meet its primary endpoint, leading to a loan default and discontinuation of the study.

Syros Pharmaceuticals presented interim results from its Phase 2 SELECT-AML-1 trial, indicating that adding tamibarotene to venetoclax and azacitidine did not improve response rates in AML patients with RARA overexpression.

Syros Pharmaceuticals has discontinued enrollment in its SELECT-AML-1 Phase 2 clinical trial due to a low probability of demonstrating superiority of the triplet regimen over the doublet regimen based on an interim analysis.

Syros Pharmaceuticals' stockholders approved key proposals at their 2024 annual meeting, including an increase in authorized shares and an amendment to the equity incentive plan.